Last checked at 23 Jul 2013 07:00
Scancell Holdings Plc
("Scancell"or the "Company")
Director Shareholdings
The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:
Director | No. of Shares purchased
| Price at which shares purchased | No. of shares held pursuant to transaction (% of ISC following transaction) |
David Evans | 30,000 | 31.8 pence | 5,130,000 (2.6%)
|
Kate Cornish-Bowden | 45,000 | 32.0 pence | 45,000 (0.02%)
|
For Further Information:
Scancell Holdings Plc Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO | + 44 (0) 74 2323 0 497
| |
Cenkos Securities: | +44 (0) 20 7397 8900 | |
Camilla Hume Stephen Keys | ||
FTI Consulting | +44 (0) 20 7831 3113 | |
Simon Conway Mo Noonan |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.